title: Three years of liraglutide treatment offers continuously optimal glycemic control in a pediatric patient with maturity-onset diabetes of the young type 3.
abstract: Sulfonylureas (SUs) are recommended as the first-line pharmacological treatment in patients with uncontrolled maturity-onset diabetes of the young type 3 (MODY3). In contrast, glucagon-like peptide-1 (GLP-1) receptor agonists have the advantages of a low risk of hypoglycemia and maintained β-cell function. We report a pediatric patient with MODY3 treated with a GLP-1 receptor agonist, liraglutide. A 12-year-old Japanese girl with MODY3 had been treated with insulin for 6 months since the time of diagnosis. After genetic analysis, we switched her treatment from insulin to liraglutide. After switching to liraglutide, the patient maintained optimal glycemic control with hemoglobin A₁c levels of 6.8%-7.5% and had postprandial C-peptide levels >3.0 ng/mL during a 3-year treatment period. No adverse events associated with liraglutide were observed. GLP-1 receptor agonists are the potential medications for patients with MODY3 who maintain residual insulin secretion.
authors.forename: Tatsuhiko
authors.initials: T
authors.lastname: Urakami
authors.forename: Masako
authors.initials: M
authors.lastname: Habu
authors.forename: Misako
authors.initials: M
authors.lastname: Okuno
authors.forename: Junichi
authors.initials: J
authors.lastname: Suzuki
authors.forename: Shori
authors.initials: S
authors.lastname: Takahashi
authors.forename: Tohru
authors.initials: T
authors.lastname: Yorifuji
mesh_terms: D001786:Blood Glucose / Q000187:drug effects* / Q000378:metabolism; D015190:Blood Glucose Self-Monitoring; D002648:Child; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000069450:Liraglutide / Q000627:therapeutic use*; D008991:Monitoring, Physiologic
chemical_list: D001786:Blood Glucose; D000069450:Liraglutide